SPARC and gastric cancer: This study utilized an integrative pipeline to finalize seventeen potential therapeutic targets with prognostically adverse effects in gastric cancer: BGN, BMP1, COL18A1, COL1A1, COL1A2, COL4A1, COL5A2, FAP, LOXL2, MMP14, NID2, PDGFRB, SERPINH1, SPARC, THBS2, THY1, and VCAN.